Sandoz Launches Global Biosimilars Initiative
‘Act4Biosimilars’ Aims To Increase Adoption By At Least 30% In 30 Countries By 2030
Sandoz has launched a global campaign to increase uptake of biosimilars, under the banner of Act4Biosimilars. The initiative aims to increase the adoption of biosimilars by at least 30% in at least 30 countries by 2030.
You may also be interested in...
Accord and Sandoz were the big winners at the Global Generics & Biosimilars Awards 2022 in Frankfurt, with other firms recognized including Beximco, Centrient, Dr Reddy’s, Eurofarma, Samsung Bioepis, Shanghai Henlius Biotech and Stada, as well as the US Biosimilars Forum.
In the wake of a recent paper which concluded that moving patients between two different biosimilar versions of the same brand biologic was safe and effective, Generics Bulletin speaks to Sandoz Inc executive director of scientific affairs Hillel Cohen about the growing importance of – and challenges to – biosimilar-to-biosimilar switching.
At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.